Relapsed/Refractory Sarcomas, Solid Tumors
Conditions
Keywords
ETOPOSIDE (VP-16), SAHA (SUBEROYLANILIDE HYDROXAMIC ACID) (Vorinostat), Pediatric, 10-096, POETIC, phase II component: the population will be restricted to relapsed/refractory sarcomas.
Brief summary
The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, vorinostat and etoposide, is in treating cancer. The medication etoposide is a standard medication used in the treatment of cancer in children. Vorinostat is an experimental drug which targets a protein(s) that control the way cancer cells grow and divide. Vorinostat is approved by the FDA in adults with certain cancers but not approved yet in children. There are two parts to this study. In the first part of this study, the phase I portion, a safe dose of the combination, vorinostat and etoposide. The goal of second part of this study, the phase II portion, is to see how effective the combination of vorinostat and etoposide is in treating cancer.
Interventions
DRUGVorinostat and Etoposide
Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
Sponsors
Merck Sharp & Dohme LLC
Phoenix Children's Hospital
Milton S. Hershey Medical Center
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Hospital Colorado
University of Florida
Alberta Children's Hospital
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Children's Mercy Hospital Kansas City
Johns Hopkins All Children's Hospital
Arnold Palmer Hospital for Children
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
* Phase I Component: Histologic confirmation of relapsed/refractory solid tumors, including tumors of the central nervous system that have failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist. Patients with diffuse pontine glioma are not required to have histologic confirmation of disease, and are eligible with radiologic confirmation. Phase II Component: the population will be restricted to relapsed/refractory sarcomas * Patient must be between 4-21 years of age at the time of study enrollment. Efforts will be made to enroll patients \<13 years of age so that adequate information about the biologic effects of this agent in younger patients can be obtained. * Patient must have Karnofsky \> or = to 60% for patients \>10 years of age; Lansky Play Scale \> or = to to 60 for children \< or = to 10 years of age * Patient must have a life expectancy of \> 8 weeks. * There is no limit to the number of prior treatment regimens provided that performance status and life expectancy meet the criteria above. * Absolute neutrophil count (ANC) ≥ 1000 / mcL * Platelets ≥100,000 / mcL (transfusion not permitted) * Hemoglobin ≥ 9 g/dL qualifications (transfusion permitted) * Coagulation Prothrombin Time or INR ≤ 1.5x upper limit of normal (ULN) * Serum creatinine ≤ 1.5x upper limit of normal (ULN) OR calculated creatinine clearance ≥ 60 mL/min for patients with creatinine levels \> 1.5x institutional ULN. or calculated creatinine clearance Creatinine clearance should be calculated per institutional standard. * Serum total bilirubin ≤ 1.5 x ULN Patient's who don't meet this criteria must have a Direct bilirubin ≤ 1.5 x ULN * AST (SGOT) and ALT (SGPT) Alkaline Phosphatase (liver fraction) ≤ 2.5 x ULN. If AST or ALT is \> 2.5 x ULN, then the liver fraction of Alkaline Phosphatase should be ≤ 2.5 x ULN * Phase I component: Patients may have measurable or non-measurable disease. Phase II component: Patients may only have measurable disease. * Patient must have no persistent toxicities from prior therapy \> or = to Grade 2 with the exception of hematologic indices (i.e. hemoglobin, WBC, ANC, ALC). * For females of childbearing potential, a negative serum pregnancy test must be documented within 72 hours of receiving the first dose of vorinostat. * Patient, or the patient's legal representative, has voluntarily agreed to participate by giving written informed consent. * Female patients of childbearing potential must be willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study, starting with visit 1. * Male patients must agree to use an adequate method of contraception for the duration of the study. * Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. * Myelosuppressive chemotherapy: At least 2 weeks must have elapsed since the administration of previous therapy. Six weeks must have elapsed since administration of nitrosoureas or mitomycin C. Seven days must have elapsed since the administration of G-CSF and/or GM-CSF. * Biologic agents: At least 14 days must have elapsed since the completion of therapy with a biologic agent such as a monoclonal antibody. Seven days must have elapsed since the last dose of retinoids. * Radiation therapy (XRT): \> or = to 2 weeks must have elapsed for local XRT (small port); \> or = to 6 months must have elapsed if prior radiation to \> or = to 50% of the pelvis or if other substantial bone marrow irradiation, including total body irradiation. * Patient must be able to swallow capsules. * Patient must have an available archival/pre-treatment block or fresh tumor biopsy for molecular profiling to be performed.
Exclusion criteria
* A patient meeting any of the following criteria is not eligible to participate in this study: * Patients currently participating or has participated in a study with an investigational compound or device within 4 weeks of initial dosing with study drugs. * Patients with a prior history of treatment with HDAC inhibitors ( e.g. SNDX-275/entinostat, LAQ-824, LBH589, PXD-101/belinostat, etc). Patients who have received Valproic acid will be excluded from this study. * Patients with non CNS primary tumors who have known brain metastases or symptomatic CNS disease (e.g. cranial nerve abnormalities) without cytologic abnormality in the CSF should be excluded from this clinical trial because of their poor prognosis and known propensity for the development of progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with metastatic CNS tumors will not be excluded from enrollment on this study in the phase I component only. * Patients who have undergone prior autologous stem cell transplantation or allogeneic transplantation. * Uncontrolled intercurrent illness or circumstances that could limit compliance with the study requirements including, but not limited to: ongoing or active bacterial or fungal infection, acute or chronic graft versus host disease, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations. * Patients who are pregnant or breastfeeding, or expecting to conceive within the projected duration of the study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorinostat, lactating patients will be excluded from this study. * Patients known to be Human Immunodeficiency Virus (HIV)-positive. * Patients with known hypersensitivity to the components of the study drugs or their analogs. * Patients with symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions is eligible. * Patients who are at the time of signing informed consent, a regular user of any illicit drugs, substance abuser or who have a recent history of drug or alcohol abuse. * Patients with a known history of Hepatitis B or C. * Patients who have a history of gastrointestinal surgery or other procedures that might in the opinion of the investigator, interfere with the absorption or swallowing of the study drug. * Patients who are unable to take or tolerate oral medications on a continuous basis. * Patients with a history of a prior malignancy who have undergone potentially curative therapy with no evidence of that disease for five years or patients, who are deemed low risk for recurrence by his/her treating physician are permitted to enroll.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To Establish the Dose Limiting Toxicity (DLT) | Patients will be assessed in 3-week cycles. | of the novel combination vorinostat and etoposide in pediatric patients with refractory solid tumors including tumors of the central nervous system. The Toxicity will be evaluated according to NCI CTCAE Version 4.0. |
| To Establish the Maximum Tolerated Dose (MTD) | 1 year | of the novel combination vorinostat and etoposide in pediatric patients with refractory solid tumors including tumors of the central nervous system. |
| To Establish the Efficacy (CR (Complete Response) + PR (Partial Response) Rate) | 1 year | of the novel combination vorinostat and etoposide in pediatric patients with relapsed/refractory sarcoma. Evaluation for response will be determined by Revised RECIST guideline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To Evaluate the Efficacy (CR (Complete Response) + PR (Partial Response) Rate) | 1 year | of the novel combination vorinostat and etoposide in pediatric patients enrolled in the phase I component of the study. Evaluation for response will be determined by Revised RECIST guideline. |
| To Evaluate the Biologic Effects Using Histone Acetylation, Gene Expression Profiling, and Histone Phosphorylation Profiling. | 2 years | of the novel combination of vorinostat and etoposide in pediatric patients with refractory solid tumors including central nervous system tumors |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1 100 mg/m2 Etoposide, 125 mg/m2 Vorinostat + Data Migration | 7 |
| Dose Level 2 100 mg/m2 Etoposide, 160 mg/m2 Vorinostat + Data Migration | 3 |
| Dose Level 3 100 mg/m2 Etoposide, 210 mg/m2 Vorinostat + Data Migration | 3 |
| Dose Level 4 100 mg/m2 Etoposide, 270 mg/m2 Vorinostat + Data Migration | 9 |
| Phase II Dose Vorinostat 270 mg/m2; Etoposide 100 mg/m2 + Data Migration | 5 |
| Total | 27 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Not treated | 1 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Dose Level 1 | Total | Phase II Dose | Dose Level 4 | Dose Level 3 | Dose Level 2 |
|---|---|---|---|---|---|---|
| Age, Continuous | 11 years | 13 years | 13.6 years | 10.2 years | 11.7 years | 12 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 4 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 23 Participants | 3 Participants | 8 Participants | 2 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 5 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 4 Participants | 20 Participants | 4 Participants | 8 Participants | 2 Participants | 2 Participants |
| Region of Enrollment United States | 7 Participants | 27 Participants | 5 Participants | 9 Participants | 3 Participants | 3 Participants |
| Sex: Female, Male Female | 3 Participants | 14 Participants | 3 Participants | 4 Participants | 3 Participants | 1 Participants |
| Sex: Female, Male Male | 4 Participants | 13 Participants | 2 Participants | 5 Participants | 0 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 5 / 7 | 2 / 3 | 1 / 3 | 4 / 9 | 3 / 5 |
| other Total, other adverse events | 7 / 7 | 3 / 3 | 3 / 3 | 9 / 9 | 5 / 5 |
| serious Total, serious adverse events | 3 / 7 | 3 / 3 | 1 / 3 | 3 / 9 | 4 / 5 |
Outcome results
Primary
To Establish the Dose Limiting Toxicity (DLT)
of the novel combination vorinostat and etoposide in pediatric patients with refractory solid tumors including tumors of the central nervous system. The Toxicity will be evaluated according to NCI CTCAE Version 4.0.
Time frame: Patients will be assessed in 3-week cycles.
Population: Data were not collected
Primary
To Establish the Efficacy (CR (Complete Response) + PR (Partial Response) Rate)
of the novel combination vorinostat and etoposide in pediatric patients with relapsed/refractory sarcoma. Evaluation for response will be determined by Revised RECIST guideline
Time frame: 1 year
Population: Data were not collected
Primary
To Establish the Maximum Tolerated Dose (MTD)
of the novel combination vorinostat and etoposide in pediatric patients with refractory solid tumors including tumors of the central nervous system.
Time frame: 1 year
Population: Data were not collected
Secondary
To Evaluate the Biologic Effects Using Histone Acetylation, Gene Expression Profiling, and Histone Phosphorylation Profiling.
of the novel combination of vorinostat and etoposide in pediatric patients with refractory solid tumors including central nervous system tumors
Time frame: 2 years
Population: Data were not collected
Secondary
To Evaluate the Efficacy (CR (Complete Response) + PR (Partial Response) Rate)
of the novel combination vorinostat and etoposide in pediatric patients enrolled in the phase I component of the study. Evaluation for response will be determined by Revised RECIST guideline.
Time frame: 1 year
Population: Data were not collected